Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 9/20 | 0.38 |
| ▸ | HSP90B1 | P14625 | 4/20 | 0.38 |
| ▸ | NAMPT | P43490 | 5/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | GPR6 | P46095 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18819907 | 0.86 | HSP90AA1 (0.38) | HSP90AA1HSP90B1 | |
| SCHEMBL18806180 | 0.82 | CDK1 (0.44) | HSP90AA1HSP90B1HPGD | |
| SCHEMBL20203643 | 0.80 | HSP90AA1 (0.40) | HSP90AA1HSP90B1 | |
| SCHEMBL20203457 | 0.80 | GRM5 (0.49) | HSP90AA1NAMPTHPGD | |
| SCHEMBL20203582 | 0.80 | KDR (0.40) | HSP90AA1 | |
| SCHEMBL23733468 | 0.80 | NPC1 (0.42) | HSP90AA1 | |
| SCHEMBL23733453 | 0.79 | HSP90AA1 (0.36) | ACEHSP90AA1HSP90B1 | |
| SCHEMBL20203603 | 0.79 | CDK1 (0.46) | HSP90AA1HSP90B1NAMPT | |
| SCHEMBL23733491 | 0.79 | CYP2C19 (0.38) | HSP90AA1HSP90B1 | |
| SCHEMBL22876985 | 0.79 | HDAC3 (0.40) | HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11084814-B2 | Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof | TEIJIN PHARMA LIMITED (JP) | 2021-08-10 | — | — | US | disclosed |
| EP-3546458-B1 | ((PYRIDIN-2-YL)-AMINO)PYRIDO[3,4-D]PYRIMIDINE AND ((PYRIDAZIN-3-YL)-AMINO)PYRIDO[3,4-D]PYRIMIDINE DERIVATIVES AS CDK4/6 INHIBITORS FOR TREATING E.G. RHEUMATOID ARTHRITIS, ARTERIOSCLEROSIS, PULMONARY FIBROSIS, CEREBRAL INFARCTION OR CANCER | TEIJIN PHARMA LTD (JP) | 2021-01-06 | — | — | EP | disclosed |
| WO-2018097297-A1 | PYRIDO[3, 4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 帝人ファーマ株式会社 | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11084814-B2 | Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof | CDK4, CDK6, CDK16 | ACE 404/4885HSP90AA1 4289/4885HSP90B1 3570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.